CORAL GABLES, FL/ ACCESSWIRE / February 21, 2019 / The future of the biotech stock market is dependent on whether medical experts have the ability to continue pioneering advancements in medicine and other innovative solutions to curing diseases. The biotech industry is relatively new but still possesses great potential for driving medical progress. Over the past few years, we've witnessed companies taking leaps forward in DNA technology in the form of personalized medicine as well as a general understanding that drug treatments must be designed with the understanding that every patient can react differently to the treatment. As companies in the biotech sector continue to develop medicines that address the significant needs of patients, these innovations could catalyze significant investor attention. Premier Health Group (PHGRF) (PHGI), AVEO Pharmaceuticals Inc (AVEO), Adial Pharmaceuticals Inc (ADIL), and Tenax Therapeutics Inc (TENX) represent four biotech stocks that are testing their limits on Thursday.
Premier Health Group (PHGRF) (PHGI) is a Canadian publicly traded company strategically poised to take advantage of potential opportunities in the global healthcare industry. The Company is working to develop innovative healthcare approaches that combine human skill-based expertise with emerging technologies. Whereas other companies in the sector have clouded focuses, Premier's patient-centric model has resulted in an ecosystem of over 100,000 active patients, with plans to rapidly increase that number both domestically and internationally.
Premier Health Group (PHGRF) (PHGI), and its executive leadership team have an impressive track record of successfully creating value in healthcare and technology enterprises. Earlier this month, the Company provided investors with a corporate update detailing several momentous milestones that the Company surpassed over the last few months.
Premier Health Group (PHGRF) (PHGI) successfully acquired Cloud Practice Inc., a healthcare technology company that provides cloud-based electronic medical records software applications for physicians throughout Canada. Cloud Practice's suite of products includes: Juno EMR, a cloud-based EMR solution; ClinicAid, a medical billing software; and MyHealthAccess, an online patient portal.
In an attempt to focus their expansion efforts into global markets, Premier Health Group (OTC:PHGRF) (CSE:PHGI) recently announced a partnership with a major online healthcare company in China, 360 Health. The parent company, 360 Security Technology, is a leading online service company in China with a market capitalization of over $20 billion USD as of February 14, 2019.
AVEO Pharmaceuticals Inc (AVEO) announced earlier this month data from the Company's presentation from their Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC).
Per the details from the presentation, Michael Bailey, president, and CEO of AVEO said, "the improvement in progression-free survival in the TIVO-3 study, particularly in patients who received prior immunotherapy, is noteworthy. We are hopeful that these positive PFS outcomes translate into an improved overall survival hazard ratio when we report a more mature interim OS outcome in the fourth quarter of 2019."
Adial Pharmaceuticals Inc (ADIL) found itself in headlines today when the Company announced the pricing of an underwritten public offering of 2,475,000 shares of its common stock and warrants to purchase up to 1,856,250 shares of the Company's common stock. Each share of common stock is being sold together with a warrant to purchase 0.75 of one share of common stock at a combined price to the public of $3.25.
Per the specific details of the offering, Adial also has granted to the underwriter a 45-day option to purchase up to an additional 371,250 shares of common stock and/or warrants to purchase up to 278,437 shares of common stock, at the public offering price fewer discounts and commissions.
Tenax Therapeutics Inc (TENX), a specialty pharmaceutical company focused on identifying and developing drugs that address diseases with a high unmet medical need, announced earlier this month that the Company's leadership team would present and conduct one-on-one meetings at the 2019 BIO CEO & Investor Conference in New York, NY.
In anticipation of news related to the results of the Company presentation, Tenax's shares enjoyed a 6.99% boost in mid-afternoon trading on Thursday, with shares trading at $1.29 per share.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: